Stockscreener 앱 받기
3.41
6.56%
0.21
시간 외 거래:
3.39
-0.02
-0.59%
전일 마감가:
$3.20
열려 있는:
$3.19
하루 거래량:
17.02M
Relative Volume:
0.91
시가총액:
$1.83B
수익:
$66.41M
순이익/손실:
$-559.78M
주가수익비율:
-2.8365
EPS:
-1.2022
순현금흐름:
$-328.09M
1주 성능:
-6.06%
1개월 성능:
+7.91%
6개월 성능:
-0.29%
1년 성능:
-29.40%
1일 변동 폭
$3.18
$3.455
1주일 범위
$3.10
$3.59
52주 변동 폭
$2.77
$7.18
리커젼 파마 Stock (RXRX) Company Profile
명칭
Recursion Pharmaceuticals Inc
전화
(385) 269-0203
주소
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.41 | 1.72B | 66.41M | -559.78M | -328.09M | -1.2022 |
VRTX
Vertex Pharmaceuticals Inc
|
519.51 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.74 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.54 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
146.69 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
205.11 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
리커젼 파마 Stock (RXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-07-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-22 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 개시 | Needham | Buy |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-04 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 개시 | Berenberg | Buy |
| 2021-05-11 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Goldman | Neutral |
| 2021-05-11 | 개시 | JP Morgan | Neutral |
| 2021-05-11 | 개시 | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 개시 | SVB Leerink | Outperform |
모두보기
리커젼 파마 주식(RXRX)의 최신 뉴스
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
Recursion Pharma CEO Najat Khan sells $78,822 in stock By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals (RXRX) CEO and President Najat Khan Sells 22,408 Shares - GuruFocus
Recursion Pharma CEO Najat Khan sells $78,822 in stock - investing.com
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Khan Najat - Moomoo
Recursion Pharmaceuticals CEO Najat Khan Sells 22,408 Shares Under 10b5-1 Plan - Kalkine Media
Recursion Pharmaceuticals (NASDAQ:RXRX) Trades Active As Small-Caps Wobble - Kalkine Media
Recursion (NASDAQ: RXRX) CEO sells 22K shares under preset plan - Stock Titan
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today - Yahoo Finance
Recursion Pharmaceuticals Tokenized Stock (Ondo) price today, RXRXon to USD live price, marketcap and chart - CoinMarketCap
Recursion Pharmaceuticals Stock Short Interest Falls to 34.79% - Moomoo
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
2 Beaten-Down Stocks to Avoid Right Now - theglobeandmail.com
AI in Pharmaceutical Market to Hit USD 48.43 Billion by 2035, Growing at 31.76% CAGR – SNS Insider - GlobeNewswire Inc.
Penny Stocks To ResearchSeptember 6th - MarketBeat
Penny Stocks To Follow NowSeptember 5th - MarketBeat
Recursion Pharmaceuticals Inc (RXRX) Stock Price, Quote, News & History - Benzinga
RXRX Tightens Spending As AI Drug Platform Gains Traction - timothysykes.com
RXRX Tightens Cash Burn As AI Drug Pipeline Advances - StocksToTrade
RXRX Tightens Costs As AI Drug Pipeline Advances - timothysykes.com
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report? - Yahoo Finance
$Recursion Pharmaceuticals (RXRX.US)$ - Moomoo
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? - The Globe and Mail
Recursion Pharmaceuticals director Blake Borgeson sells $100,200 in stock By Investing.com - Investing.com Australia
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake - Moomoo
Recursion Pharmaceuticals Stock (RXRX) Opinions on AI Drug Discovery Pipeline - Quiver Quantitative
Recursion (NASDAQ: RXRX) director sells 30,000 shares in planned trade - Stock Titan
RXRX Stock Rallies As AI Drug Platform Tightens Cash Burn - StocksToTrade
Recursion Pharmaceuticals Earnings Call Shows Efficient Progress - TipRanks
Recursion (RXRX) Range: Ends Down by 4.86% at $3.33 in Latest Trading; Range Check: the Current Price Sits Inside the Supplied Technical Range for the Current SessionRisk Parity Rebalance - vinanet.vn
Recursion Pharmaceuticals Stock Climbs 13% As AI Drug Pipeline Progress And Spending Cuts Boost Sentiment - TIKR.com
Recursion, Novavax, Crispr Therapeutics Stocks Slip Premarket After Cancer Therapy RallyRecursion Phar - Benzinga
RXRX Stock Steadies As AI Drug Platform Gains Traction And Cash Burn Tightens - StocksToTrade
Recursion Pharmaceuticals Stock (RXRX) Opinions on Clinical Pipeline and AI Platform Developments - Quiver Quantitative
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Hallett David - Moomoo
Recursion (NASDAQ: RXRX) CEO's 80K shares withheld for RSU taxes - Stock Titan
Recursion (NASDAQ: RXRX) CSO sees 26K shares withheld for taxes - Stock Titan
Recursion Pharmaceuticals Inc (RXRX) News, Articles, Events & Latest Updates - Stocktwits
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci - The Globe and Mail
Recursion Pharmaceuticals (RXRX) Slips 1.58% as Stock Holds Above Key $2.95 SupportTriple EMA - vinanet.vn
Recursion Pharmaceuticals (RXRX) Dips 1.42% to $3.12 as Key Support Holds at $2.96Wave Truncation - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma - Yahoo Finance
Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $5.3 - Moomoo
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Stock Dropped, So What Is Behind The Move? - Sahm
RXRX|Recursion Pharmaceuticals Inc|Price:3.160|Chg%:-0.150 - TradingKey
Recursion Pharmaceuticals Stock Short Interest Rises to 35.35% - Moomoo
Jim Cramer: Utilities Stocks 'Oversold,' Fastly 'Back From Abyss'Cloudflare (NYSE:NET), Akamai Technol - Benzinga
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
$Recursion Pharmaceuticals (RXRX.US)$ panic selling by retail investors... [Awkward] - Moomoo
리커젼 파마 (RXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.75%
3.18%
자본화:
|
볼륨(24시간):